UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes in the country.

The once-daily tablet saxa / dapa FDC combines saxagliptin 5mg, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with dapagliflozin 10mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

The tablet received marketing authorisation from the European Commission on 19 July last year and is indicated in adults aged 18 and older with type 2 diabetes in order to improve glycaemic control.

AstraZeneca UK country president Lisa Anson said: “Almost three-quarters (74%) of people with type 2 diabetes in the UK are not reaching the recommended HbA1c target of 6.5%, which means they are at increased risk of the complications associated with the condition.

“AstraZeneca is pleased to offer another treatment option in the diabetes portfolio to help patients reach their targets, enabling clinicians to continue oral therapy with a once-daily tablet.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"If used in combination with a sulphonylurea (SU), a reduction in the SU dose may be needed to minimise the risk of hypoglycemia."

The European Commission approved the tablet based on data from three Phase III randomised, double-blind, active / placebo-control, parallel group, multi-centre clinical trials carried out in 1169 adult subjects with type 2 diabetes.

Saxa / dapa FDC can be used in patients with mild renal impairment and should be avoided in patients with moderate-to-severe renal impairment.

Patients with end-stage renal disease (ESRD) should avoid taking this tablet.

If used in combination with a sulphonylurea (SU), a reduction in the SU dose may be needed to minimise the risk of hypoglycemia.

The tablet is not licensed for weight loss or blood pressure reduction.